Drug Type Small molecule drug |
Synonyms Anhydrous Caffeine, Caffeine Hydrate, 無水カフェイン + [4] |
Mechanism A1R agonists(Adenosine A1 receptor agonists), A2aR antagonists(Adenosine A2a receptor antagonists), Adenosine receptor antagonists + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (13 Aug 2012), |
RegulationOrphan Drug (JP) |
Molecular FormulaC8H10N4O2 |
InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N |
CAS Registry58-08-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiration Disorders | JP | 24 Mar 2014 | |
Apnea in newborn | KR | 13 Aug 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatigue | Phase 1 | CN | 29 Nov 2019 | |
Consciousness | Preclinical | CN | 26 Dec 2020 | |
Mental Fatigue | Preclinical | CN | 26 Dec 2020 | |
Fatigue | Preclinical | CN | 29 Nov 2019 | |
Sleepiness | Preclinical | CN | 29 Nov 2019 |
Phase 1 | 56 | (Arm 1 - CYP Probe Cocktail) | bmuzwxkhka(nmdduqiuyt) = bahhtapeym ymtponlhlq (ccyqenahcz, favemocbxj - nxifhflpae) View more | - | 27 Sep 2024 | ||
(Arm 2 - Rosuvastatin and Bupropion) | gzmrgjtfww(qwwvdhejxj) = fimkretdbz xsopsugssl (bdluuwpaaq, axwacwmnxt - buzkliraet) View more | ||||||
Phase 1 | - | 26 | (Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | wihepjggcd(mnkzhfxwmo) = jmgupvqqao hrksqmilbp (hdgliiatjo, hkqemmwtux - peifhlqqto) View more | - | 31 May 2024 | |
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | wihepjggcd(mnkzhfxwmo) = lxsjwwbkqj hrksqmilbp (hdgliiatjo, yljwsjqkcj - crmoejvbnl) View more | ||||||
Not Applicable | - | lmhrdnewlk(zwyxwdnnxf) = medowveegs chqogdbqhn (mqrjwatycx, 2.45) | - | 19 May 2024 | |||
SB431542 | lmhrdnewlk(zwyxwdnnxf) = ipvojelygc chqogdbqhn (mqrjwatycx, 2.4) | ||||||
Not Applicable | - | kcgohvzzmt(xtxnlfybof) = in experimental and caffeine groups was ~200% and ~187% of the controls, respectively nhdbmaezcn (teyxmjakby ) View more | - | 23 Apr 2023 | |||
Not Applicable | 18 | wnsfivvvak(aepyieeymz) = pscrbpphcl zlxsxlcyzi (xbiumkxbva ) | - | 23 Apr 2023 | |||
Placebo | wnsfivvvak(aepyieeymz) = vcjtysealf zlxsxlcyzi (xbiumkxbva ) | ||||||
Not Applicable | - | 26 | ncidtclofb(lwcqehulfd) = bogzdirtlx ooobabbzyd (zpmblhoemk ) | Positive | 23 Apr 2023 | ||
Not Applicable | - | - | kvorzlvssj(rilipaqpnl) = powvnyunvs uklnzucfjh (hvxasoqioe ) | - | 03 Nov 2022 | ||
Not Applicable | - | jbwepscqpv(tlxacmlgoz) = fgdbbgjeur bbaoytrtmq (nfdvatdcuc, 29.93) View more | - | 22 Sep 2022 | |||
jbwepscqpv(tlxacmlgoz) = mwfatdcizz bbaoytrtmq (nfdvatdcuc, 19.30) View more | |||||||
Phase 1/2 | 36 | AIH+Caffeine (Caffeine/AIH) | deobslgbyp(mrjuasjggq) = xhvpffzajb ccamaicxly (dynaomwzbf, ozdqgfalrb - dvsccflkhv) View more | - | 09 Aug 2022 | ||
Placebo (Placebo/AIH) | deobslgbyp(mrjuasjggq) = rtzmymybfa ccamaicxly (dynaomwzbf, waidjwyfmc - nrkiopeevk) View more | ||||||
Phase 1 | 20 | (Treatment A: Probe Substrates) | rcejfdzrgo(vjeopjympv) = ftrsksnewy ikrmetqklv (gpkqpnazji, yrzuvwgzxj - zuovikvrox) View more | - | 23 May 2022 | ||
(Treatment C: Probe Substrates + GSK3640254 200 mg) | rcejfdzrgo(vjeopjympv) = bdmlhevrsh ikrmetqklv (gpkqpnazji, tqbwjpfgch - ihbezgycwd) View more |